Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma

Meng Li, Hong Zhao, Xiaosong Zhang, Laura D. Wood, Robert A. Anders, Michael A. Choti, Timothy M. Pawlik, Hubert D. Daniel, Rajesh Kannangai, G. Johan A. Offerhaus, Victor E. Velculescu, Linfang Wang, Shibin Zhou, Bert Vogelstein, Ralph H. Hruban, Nick Papadopoulos, Jianqiang Cai, Michael S. Torbenson, Kenneth W. Kinzler

Research output: Contribution to journalArticle

Abstract

Through exomic sequencing of ten hepatitis C virus (HCV)-associated hepatocellular carcinomas (HCC) and subsequent evaluation of additional affected individuals, we discovered novel inactivating mutations of ARID2 in four major subtypes of HCC (HCV-associated HCC, hepatitis B virus (HBV)-associated HCC, alcohol-associated HCC and HCC with no known etiology). Notably, 18.2% of individuals with HCV-associated HCC in the United States and Europe harbored ARID2 inactivation mutations, suggesting that ARID2 is a tumor suppressor gene that is relatively commonly mutated in this tumor subtype.

Original languageEnglish (US)
Pages (from-to)828-829
Number of pages2
JournalNature genetics
Volume43
Issue number9
DOIs
StatePublished - Sep 1 2011

    Fingerprint

ASJC Scopus subject areas

  • Genetics

Cite this

Li, M., Zhao, H., Zhang, X., Wood, L. D., Anders, R. A., Choti, M. A., Pawlik, T. M., Daniel, H. D., Kannangai, R., Offerhaus, G. J. A., Velculescu, V. E., Wang, L., Zhou, S., Vogelstein, B., Hruban, R. H., Papadopoulos, N., Cai, J., Torbenson, M. S., & Kinzler, K. W. (2011). Inactivating mutations of the chromatin remodeling gene ARID2 in hepatocellular carcinoma. Nature genetics, 43(9), 828-829. https://doi.org/10.1038/ng.903